What is a peptide? The plain-language definition behind the headlines

The word peptide is doing a lot of work right now. It’s printed on supplement bottles, attached to billion-dollar drugs, and traded across forums where the same vial gets called a research chemical, a biohack, and a treatment, all on the same page.

Strip the marketing off and the actual definition is simple. A peptide is a short chain of amino acids. That’s it. Everything else — whether it’s a drug, a research compound, or a fragment of something your body already makes — is downstream of that one fact.

What a peptide actually is

Amino acids are the small building blocks proteins are made from. There are twenty of them in humans. String two together and you’ve got a dipeptide. String fifty together and you’ve got something most chemists would still call a peptide. String a few hundred together and you’ve crossed into protein territory. The line is fuzzy — most sources put it around fifty residues — and the chemistry is the same on both sides. Size is the difference, not kind.

Inside the body, peptides do specific work. Some are hormones — insulin is a peptide of fifty-one amino acids, and it’s been a drug since 1922. Some are immune signals. Some are structural. Some are the messengers that tell one organ what another is doing. The body makes hundreds of them; the ones we name and study tend to be the ones with a clear job that researchers can isolate.

Shorthand: amino acids are the parts, peptides are short assemblies, proteins are long ones. Peptide therapy almost always means short assemblies — usually under fifty residues — given as injections, sprays, or sometimes pills.

How peptides work biologically

Most peptides in the body act as signals. They bind to a receptor on a cell — usually on the outside of the cell — and tell that cell to change what it’s doing. Burn more fuel. Hold more water. Release a different hormone. Grow new blood vessels at the site of an injury. The body uses peptides to coordinate, the same way a building uses electrical signals to coordinate the lights.

That signalling is why peptide drugs can be precise. A peptide drug imitates a signal the body already understands. The receptors are already there. The downstream machinery is already wired. The drug arrives, fits the receptor, and the existing wiring does the work — through pathways nature already debugged.

The catch sits in the same chemistry: most peptides break down in the stomach. Insulin, GLP-1 drugs, and most therapeutic peptides have to be injected, or formulated carefully, because swallowed plain they’d be chopped up before reaching the bloodstream. That’s a constraint of the molecule, not a quirk of any one drug.

Endogenous versus exogenous — and why the distinction matters

A peptide your body makes on its own is endogenous. A peptide you take from outside — pill, injection, nasal spray — is exogenous. Insulin is the simple case: the body makes it (endogenous), and people with type 1 diabetes inject manufactured insulin (exogenous). Same molecule, same receptor, different source.

A lot of the peptides in performance and longevity discussions are exogenous versions of fragments or analogues of something the body already makes. The argument is that the body already knows what to do with the signal, so the side-effect ceiling should be lower than a foreign drug. Reasonable starting hypothesis. Not, on its own, evidence — the body also makes oestrogen, and also makes it is not the same sentence as safe to dose at any level in any person for any indication.

Why peptide therapy became a category

A decade ago, almost nobody outside endocrinology used the word peptide outside of insulin. Three things changed that.

The first is the GLP-1 family. Semaglutide, tirzepatide, and the other drugs sold under brands like Ozempic and Mounjaro are all peptides. They mimic gut hormones that regulate appetite and blood sugar. They work — well enough that the category went from niche to nationally visible inside three years. Once peptide drugs proved out at that scale, the broader category started getting attention.

The second is the compounding pathway. US law allows licensed pharmacies to make custom drugs to fill specific prescriptions when no approved commercial product fits. That’s Section 503A of the Federal Food, Drug, and Cosmetic Act. Compounded peptides — made to order for a named patient by a licensed pharmacy — have been part of that lane for years, and the FDA keeps a list of which bulk drug substances are eligible.

The third is the research-chemical market. A whole layer of peptides — sold in vials labelled not for human consumption, shipped from grey-market suppliers, with no prescription and no quality testing — has built itself into the gap between the approved drug list and the compounded pharmacy list. That layer is what most coverage of peptides in 2025 and 2026 is actually about: substances bought from sites that legally cannot sell them for use in people, by people who use them anyway.

That’s the messy reality the word peptide now lives inside. The same word covers insulin, GLP-1 drugs, compounded medicine, and a vial of something a stranger shipped from a warehouse.

What the FDA is doing in 2026 and 2027

The current FDA review activity is the part most readers find by accident, usually through a podcast that flattens the details. The short version is that the agency’s Pharmacy Compounding Advisory Committee — an advisory panel, not a drug-approval body — has two meetings on its calendar to look at twelve peptides as a coherent batch. Seven peptides are on the July 23–24, 2026 meeting docket per the April 2026 Federal Register notice. Five more are queued for a second meeting before the end of February 2027. The committee recommends; the FDA then writes the actual rule, usually months later.

This is the regulatory gate between the research-chemical layer and the compounding pharmacy layer. A favourable vote followed by favourable rulemaking opens a peptide up to be dispensed by US-licensed pharmacies for a specific indication. An unfavourable vote leaves the existing situation in place. We covered the mechanics in detail in What is the PCAC.

What the word peptide doesn’t tell you

By itself, peptide doesn’t tell you whether something carries an FDA approval, is prescribable, is compoundable, is banned by sports authorities, has been well-studied in humans, or has been studied at all. It tells you the molecule is a short chain of amino acids. Everything else has to come from the specific peptide, the specific indication, and the specific evidence.

Peptides as a class are not fringe science. Insulin is a peptide. GLP-1 drugs are peptides. The class is clinically validated for the things it’s been clinically validated for. The peptides currently marketed for performance, recovery, and longevity sit in a different evidence category — mostly animal data, some early human trials, an active FDA review process, and a research-chemical supply chain doing most of the volume.

The word peptide covers an enormous range — and the regulated version of any one molecule is the version a US-licensed compounding pharmacy can prepare against a real prescription, for the specific indication the evidence actually supports. Wolverine Health is being built to be that version. Join the waitlist if you want a heads-up the day the legal pathway for a peptide you care about actually opens.